Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Virgin Galactic Holdings, Inc. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Virgin Galactic Holdings, Inc. trades at $2.86 (market cap $445.69M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 28.2× Virgin Galactic Holdings, Inc.'s market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| HALO | SPCE | |
|---|---|---|
Market Cap | $12.58B | $445.69M |
Volume | 2,179,278 | 5,128,850 |
Sector | Health | Industrials |
52-Week High | $115.22 | $7.52 |
52-Week Low | $61.63 | $2.17 |
Typical Hold Time | 1 Days | 69 Days |
Enterprise Value | $14.49B | $409.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Virgin Galactic (SPCE) trades at $2.84, down 5.65% on the day, reflecting ongoing volatility amid a bearish technical signal. The company continues to report significant losses with a net income margin of -23,867.44% (2025 financials), though it has beaten EPS estimates in recent quarters. Cash flow remains negative, but the trend is improving, with management targeting positive quarterly cash flow by 2027. Recent news highlights strong ticket demand but also a delay in commercial Delta flights to February 2027.
The outlook remains high-risk due to persistent losses and cash burn, but long-term potential exists in commercial spaceflight. Investment opportunity hinges on successful execution of the Delta program and achieving profitability targets. Key risks include execution delays, high cash burn, competitive pressures, and stock dilution. Analyst sentiment is mixed, with 29.41% buy ratings, reflecting cautious optimism amid substantial operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
